Continuum Biosciences, Inc. has facilities in Blacksburg, Virginia and Sydney, Australia. Its research is focused on improving how our bodies burn fuel as we age by targeting the mitochondria, the powerhouses of our cells.

As we grow older, our metabolic rate declines and our bodies lose the capacity for burning energy. One of the results of this is excess nutrient storage and associated diseases including obesity, diabetes, liver disease, and other metabolic conditions.

Researchers at Continuum are developing molecules that target the mitochondria, the powerhouses of the cell, which increase energy expenditure. These self-limiting uncouplers are highly specific to mitochondria and have the potential to combat multiple metabolic and age-related diseases. Continuum’s first targets for treatments are metabolic disorders associated with fatty liver disease and obesity.

Continuum Biosciences is a daughter company of Life Biosciences, which owns multiple rejuvenation biotechnology companies, each focusing on a different hallmark of aging.